{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:36:04Z","timestamp":1759775764645},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6775,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[1988,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only considerably increased estrogen concentration in plasma but also maintain the same estrone\/estradiol ratio as in normal men.<\/jats:p><jats:p>Monthly injections of PEP produce persistent elevation of the plasma estradiol levels throughout the dose interval, and rising PEP doses produce proportionately increasing steady\u2010state plasma concentrations of estradiol.<\/jats:p><jats:p>The steady\u2010state plasma concentrations of testosterone are reduced to 45, 25, and 15% of the pretreatment concentrations after treatment every fourth week with 80, 160, and 240 mg PEP, respectively.<\/jats:p>","DOI":"10.1002\/pros.2990130405","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T01:41:07Z","timestamp":1172022067000},"page":"299-304","source":"Crossref","is-referenced-by-count":8,"title":["Clinical pharmacology of polyestradiol phosphate"],"prefix":"10.1002","volume":"13","author":[{"given":"Per Olov","family":"Gunnarsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Johan","family":"Norl\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","unstructured":"Carlstr\u00f6mK CollsteL ErikssonA HenrikssonP Pousette\u00c5 StegeR von SchoultzB: A comparison of androgen status in patients with prostatic cancer treated with oral or parenteral estrogens or by orchidectomy.The Prostate(in press 1989).","DOI":"10.1002\/pros.2990140210"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990130308"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","unstructured":"StegeR Carlstr\u00f6mK CollsteL ErikssonA HenrikssonP Pousette\u00c5 von SchoultzB: Single drug parenteral estrogen treatment in prostatic cancer a study of different initial and maintenance dose regimens.The Prostate(in press 1989).","DOI":"10.1002\/pros.2990140211"},{"key":"e_1_2_1_5_2","first-page":"312","article-title":"Urinary excretion of natural estrogens in oophorectomized women treated with polyestradiol phosphate (pEP)","volume":"21","author":"Diczfalusy E","year":"1956","journal-title":"Acta Endocrinol (copenh)"},{"key":"e_1_2_1_6_2","first-page":"24","article-title":"Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma","volume":"17","author":"Leinonen P","year":"1979","journal-title":"Invest Urol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189482"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0083-6729(08)60965-6"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000472772","article-title":"Plasma concentrations of estradiol and testosterone in single\u2010Drug polyestradiol phosphate therapy for prostatic cancer","volume":"13","author":"Norl\u00e9n BJ","year":"1987","journal-title":"Eur Urol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-5347(17)49273-1","article-title":"Optimal testosterone concentration for the treatment of prostatic cancer","volume":"133","author":"Trachtenberg J","year":"1985","journal-title":"J Urol"},{"key":"e_1_2_1_11_2","first-page":"6041","article-title":"The effectiveness of complete vs partial androgen withdrawal therapy for the treatment of prostatic cancer","volume":"45","author":"Ellis WJ","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.3891\/acta.chem.scand.12-1675"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.2990130405","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.2990130405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T01:17:21Z","timestamp":1697937441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.2990130405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,1]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1988,1]]}},"alternative-id":["10.1002\/pros.2990130405"],"URL":"https:\/\/doi.org\/10.1002\/pros.2990130405","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,1]]}}}